TCRT | Alaunos Therapeutics, Inc.

Index- P/E- EPS (ttm)-0.17 Insider Own1.40% Shs Outstand239.68M Perf Week-16.60%
Market Cap119.20M Forward P/E- EPS next Y-0.13 Insider Trans0.00% Shs Float218.77M Perf Month-15.19%
Income-38.00M PEG- EPS next Q-0.04 Inst Own33.10% Short Float / Ratio10.88% / 37.01 Perf Quarter-11.73%
Sales2.90M P/S41.10 EPS this Y52.70% Inst Trans1.25% Short Interest23.81M Perf Half Y-21.57%
Book/sh0.12 P/B4.17 EPS next Y23.50% ROA-59.60% Target Price3.03 Perf Year5.77%
Cash/sh0.10 P/C5.07 EPS next 5Y- ROE-108.30% 52W Range0.45 - 4.01 Perf YTD-22.91%
Dividend- P/FCF- EPS past 5Y20.10% ROI-63.40% 52W High-87.52% Beta0.16
Dividend %- Quick Ratio2.20 Sales past 5Y-14.50% Gross Margin- 52W Low10.76% ATR0.05
Employees34 Current Ratio2.20 Sales Q/Q- Oper. Margin- RSI (14)39.15 Volatility9.21% 8.33%
OptionableYes Debt/Eq0.37 EPS Q/Q7.90% Profit Margin- Rel Volume0.69 Prev Close0.50
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume643.35K Price0.50
Recom2.20 SMA20-14.37% SMA50-12.38% SMA200-51.07% Volume444,648 Change1.07%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Resumed Wells Fargo Overweight $3
May-25-23 05:00PM
May-10-23 07:00AM
May-03-23 08:30AM
Apr-26-23 12:30PM
Mar-30-23 07:00AM
05:30PM Loading…
Mar-29-23 05:30PM
Mar-07-23 07:00AM
Feb-28-23 04:01PM
Feb-17-23 05:47AM
Jan-09-23 08:30AM
Nov-29-22 09:01AM
Nov-28-22 04:01PM
Nov-14-22 07:00AM
Nov-08-22 08:30AM
Nov-07-22 08:00AM
08:30AM Loading…
Sep-21-22 08:30AM
Sep-07-22 08:30AM
Sep-06-22 08:00AM
Aug-24-22 03:00PM
Aug-15-22 07:00AM
Aug-08-22 08:50AM
Aug-04-22 05:00PM
Jul-06-22 09:31AM
Jun-30-22 07:07AM
Jun-27-22 08:00AM
Jun-01-22 08:30AM
May-26-22 05:01PM
May-16-22 07:30AM
May-12-22 11:48AM
May-10-22 08:30AM
08:30AM Loading…
May-09-22 08:30AM
May-02-22 04:31PM
Mar-30-22 07:30AM
Mar-22-22 01:58PM
Mar-16-22 08:30AM
Mar-08-22 04:05PM
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vieser JaimeDirectorNov 29Buy0.651,250,000812,5001,250,000Dec 01 04:05 PM
Postma Robert WDirectorNov 29Buy0.65750,000487,5005,000,000Dec 01 04:05 PM